Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

BACKGROUND: Developing a cross-clade, globally effective HIV vaccine remains crucial for eliminating HIV. METHODS: This placebo-controlled, double-blind, phase 1/2a study enrolled healthy HIV-uninfected adults at low risk for HIV infection. They were randomized (1:4:1) to receive 4 doses of an adeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Stieh, Daniel J, Barouch, Dan H, Comeaux, Christy, Sarnecki, Michal, Stephenson, Kathryn E, Walsh, Stephen R, Sawant, Sheetal, Heptinstall, Jack, Tomaras, Georgia D, Kublin, James G, McElrath, M Juliana, Cohen, Kristen W, De Rosa, Stephen C, Alter, Galit, Ferrari, Guido, Montefiori, David, Mann, Philipp, Nijs, Steven, Callewaert, Katleen, Goepfert, Paul A, Edupuganti, Srilatha, Karita, Etienne, Seaman, Michael S, Corey, Lawrence, Baden, Lindsey R, Pau, Maria G, Schuitemaker, Hanneke, Tomaka, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202119/
https://www.ncbi.nlm.nih.gov/pubmed/36348617
http://dx.doi.org/10.1093/infdis/jiac445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202119/
https://www.ncbi.nlm.nih.gov/pubmed/36348617
http://dx.doi.org/10.1093/infdis/jiac445

Ejemplares similares